Fidelity Investments’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-129,638
| Closed | -$296K | – | 5783 |
|
|
2024
Q2 | $296K | Buy |
129,638
+69,698
| +116% | +$266K | ﹤0.01% | 2904 |
|
|
2024
Q1 | $259K | Sell |
59,940
-1,374
| -2% | -$4.79K | ﹤0.01% | 2942 |
|
|
2023
Q4 | $187K | Buy |
61,314
+51,182
| +505% | +$96.2K | ﹤0.01% | 2977 |
|
|
2023
Q3 | $14.6K | Sell |
10,132
-8,116
| -44% | -$15.7K | ﹤0.01% | 3965 |
|
|
2023
Q2 | $45.4K | Sell |
18,248
-946,344
| -98% | -$2.59M | ﹤0.01% | 3477 |
|
|
2023
Q1 | $2.59M | Buy |
964,592
+686,025
| +246% | +$3.3M | ﹤0.01% | 2302 |
|
|
2022
Q4 | $1.51M | Sell |
278,567
-221,161
| -44% | -$1.85M | ﹤0.01% | 2445 |
|
|
2022
Q3 | $6.24M | Buy |
499,728
+11,021
| +2% | +$126K | ﹤0.01% | 2096 |
|
|
2022
Q2 | $2.41M | Buy |
488,707
+982
| +0.2% | +$5.44K | ﹤0.01% | 2449 |
|
|
2022
Q1 | $3.71M | Buy |
487,725
+377,586
| +343% | +$3.58M | ﹤0.01% | 2438 |
|
|
2021
Q4 | $1.13M | Sell |
110,139
-688,161
| -86% | -$8.77M | ﹤0.01% | 2664 |
|
|
2021
Q3 | $10.7M | Sell |
798,300
-15,341
| -2% | -$250K | ﹤0.01% | 2104 |
|
|
2021
Q2 | $17.9M | Buy |
813,641
+41
| +0% | +$911 | ﹤0.01% | 1888 |
|
|
2021
Q1 | $19.6M | Sell |
813,600
-110,339
| -12% | -$2.56M | ﹤0.01% | 1817 |
|
|
2020
Q4 | $16.6M | Sell |
923,939
-3,365,752
| -78% | -$50.3M | ﹤0.01% | 1791 |
|
|
2020
Q3 | $49.5M | Sell |
4,289,691
-1,370,898
| -24% | -$22.6M | 0.01% | 1198 |
|
|
2020
Q2 | $137M | Buy |
5,660,589
+14,260
| +0.3% | +$236K | 0.02% | 746 |
|
|
2020
Q1 | $62.2M | Buy |
5,646,329
+9,103
| +0.2% | +$170K | 0.01% | 956 |
|
|
2019
Q4 | $149M | Buy |
5,637,226
+8,838
| +0.2% | +$207K | 0.02% | 753 |
|
|
2019
Q3 | $128M | Buy |
5,628,388
+8,316
| +0.1% | +$262K | 0.02% | 788 |
|
|
2019
Q2 | $172M | Buy |
5,620,072
+8,837
| +0.2% | +$186K | 0.02% | 700 |
|
|
2019
Q1 | $93.1M | Buy |
5,611,235
+33,481
| +0.6% | +$635K | 0.01% | 941 |
|
|
2018
Q4 | $107M | Buy |
5,577,754
+361,091
| +7% | +$13.5M | 0.01% | 825 |
|
|
2018
Q3 | $273M | Buy |
5,216,663
+313,931
| +6% | +$17.1M | 0.03% | 553 |
|
|
2018
Q2 | $213M | Buy |
4,902,732
+57,156
| +1% | +$2.45M | 0.02% | 636 |
|
|
2018
Q1 | $180M | Buy |
4,845,576
+738,932
| +18% | +$19.7M | 0.02% | 733 |
|
|
2017
Q4 | $81.5M | Buy |
4,106,644
+1,584,611
| +63% | +$34.1M | 0.01% | 1087 |
|
|
2017
Q3 | $62.8M | Buy |
2,522,033
+567,171
| +29% | +$10.5M | 0.01% | 1199 |
|
|
2017
Q2 | $34.1M | Buy |
+1,954,862
| New | +$34.2M | ﹤0.01% | 1463 |
|
Fidelity Investments's GTHX Position: Q3 2024 in Review
Fidelity Investments sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 129,638 shares — an estimated $296K sold.
Fidelity Investments first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $273M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Fidelity Investments reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Fidelity Investments sold 129,638 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $296K.
- Fidelity Investments first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- Fidelity Investments's G1 Therapeutics, Inc. Common Stock position peaked at $273M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.